凋亡相关基因p53、bcl-2、bax在前列腺组织中的相关性

Correlation of apoptosis genes of p53,bcl-2 and bax in tissue of prostate

目的探讨细胞凋亡相关基因p53、bcl-2、bax在前列腺组织中的相关性。方法收集36例前列腺癌(prostate caner,PCa)、20例前列腺增生(benign prostatic hyperplasia,BPH)和11例正常前列腺(normal prostatic,NP),应用免疫组织化学S-P法检测凋亡相关基因p53、bcl-2、bax蛋白的表达。结果①PCa和BPH组bcl-2蛋白阳性表达率明显高于NP组(P<0.05),而PCa组与BPH组阳性率差异无显著性。PCa组p53蛋白阳性表达率明显高于BPH组和NP组(P<0.01),而BPH组与NP组阳性率无显著性差异(P>0.05)。②p53与PCa分级有关,随着肿瘤分级增高而呈正相关(P<0.05);bcl-2与PCa分级有关,随着肿瘤分级增高而呈正相关(P<0.01),显示bcl-2、p53蛋白表达随着病理分级的增高而增高。PCa、BPH和NP中bax阳性表达率差异无显著性。③p53蛋白表达阳性率≤5年生存组明显高于>5年生存组,呈负相关(P<0.05);bcl-2、bax蛋白表达与生存期无关(P>0.05)。结论细胞凋亡相关基因p53、bcl-2、bax蛋白的异常表达与PCa的发生和发展、病理分级和预后有相关性。

Objective To investigate clinical significance and expression between apoptosis and the expression of the related genes ofp53,bcl-2 and bax in prostate cancer （PCa）. Methods The expression of bcl-2, bax and p53 protein and apoptosis cells were detected by immunohistochemical S-P method respectively in tissues of 36 cases of PCa, 20 BPH and 11 NP. Results （1） It showed that bcl-2 expression in Pca was significantly higher than that in NP and BPH （P〈0.05）, and there was no significant difference between PCa and BPH（P〉0.05）. p53 expression in PCa was significantly higher than that in BPH and NP （P〈0.01）, and there was no significant difference between BPH and NP（P〉0.05）. （2） In the tissue of Pca, p53 and bcl-2 expression was positively correlated with pathological grade, as PCa increased in grades （P〈0.05, P〈0.01）.It showed that expression levels of bcl-2 and p53 protein in PCa tissues increased with the progression of pathological grade. Bax positive expressing rate difference had no significance in PCa, BPH and NP. （3）The expression of p53 was frequently detected in shorter-than-5-year survival group, than it was in longer-than-5-year survival group （P〈0.05）. That of bcl-2 expression was not related to survival period （P〉0.05）. Conchmiotl The over-expression of apoptosis-related genes： bcl-2,bax and p53 might be related to the carcinogenesis, progression pathological grade and prognosis of prostate carcinoma